Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,898 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Effect of Drug Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

NCT04121078
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-906, Rifampin
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Nov 15, 2026, 5:15 AM EST
Withdrawn Phase 4 Interventional

Pilot Study: Effect of Dexamethasone vs Vicodin in Reducing Post-operative Pain

NCT04008043
View directory record Official record
Conditions
Oral Surgery
Interventions
Vicodin, Dexamethasone
Drug
Lead sponsor
Boston University
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Nov 15, 2026, 5:15 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Balance and Anti-Epileptic Drugs

NCT03338478
View directory record Official record
Conditions
Epilepsy
Interventions
Wii Balance Board
Diagnostic Test
Lead sponsor
Erik J. Kobylarz
Other
Eligibility
16 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Nov 15, 2026, 5:15 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)

NCT06596668
View directory record Official record
Conditions
Healthy
Interventions
bomedemstat, carbamazepine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Nov 15, 2026, 5:15 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

NCT04175925
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986322, BMS-986322 Placebo, famotidine
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Nov 15, 2026, 5:15 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects

NCT01402076
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tasimelteon, Rosiglitazone, Midazolam
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 17, 2014 · Synced Nov 15, 2026, 5:15 AM EST
Completed No phase listed Observational

Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

NCT00458887
View directory record Official record
Conditions
Ototoxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
management of therapy complications
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 18 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
73
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Nov 15, 2026, 5:15 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Effects of Flumazenil on Brain Excitability

NCT00015678
View directory record Official record
Conditions
Stroke, Healthy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 15, 2026, 5:15 AM EST
Completed Not applicable Interventional Results available

Study of the Effect of Calorie Supplementation on Growth in Young Children on ADHD Medication

NCT00561340
View directory record Official record
Conditions
ADHD
Interventions
Pediasure, Nutritional counseling
Dietary Supplement · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
5 Years to 9 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Nov 15, 2026, 5:15 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Investigate the Effects of Rifampin on the Pharmacokinetics of NKTR-118

NCT01533870
View directory record Official record
Conditions
Drug Induced Constipation
Interventions
NKTR-118, Rifampin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Nov 15, 2026, 5:15 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Effect of Cannabis on Cigarette Use Behavior

NCT06609083
View directory record Official record
Conditions
Cannabis Use, Tobacco Use, Cigarette Smoking
Interventions
THC 30mg, THC 5mg, THC 0mg, Cigarette Full Nicotine, Cigarette Reduced Nicotine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Nov 15, 2026, 5:15 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers

Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers

NCT03420469
View directory record Official record
Conditions
Adverse Effect of Drug Therapy Metabolism Medications (Diagnosis)
Interventions
Bupropion
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Nov 15, 2026, 5:15 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men

NCT04713254
View directory record Official record
Conditions
Healthy
Interventions
Lu AG06466, Midazolam, Metoprolol, Bupropion
Drug · Other
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Nov 15, 2026, 5:15 AM EST
Completed Phase 4 Interventional Results available

Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery

NCT00494494
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Standard Care, nepafenac
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Nov 15, 2026, 5:15 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants

NCT04901923
View directory record Official record
Conditions
Healthy Participants
Interventions
ACP-196, Itraconazole
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Nov 15, 2026, 5:15 AM EST
Completed Phase 1Phase 2 Interventional Results available

Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis

NCT01582880
View directory record Official record
Conditions
Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid, Stevens Johnson Syndrome, Lupus Erythematosus, Systemic, Rheumatoid Arthritis, Other Autoimmune Diseases
Interventions
Riboflavin
Drug
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Nov 15, 2026, 5:15 AM EST
Completed Phase 1 Interventional Results available

Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine

NCT00796991
View directory record Official record
Conditions
Advanced Melanoma
Interventions
Ipilimumab, Carboplatin, Paclitaxel, Dacarbazine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Nov 15, 2026, 5:15 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Influence of Authorized Smokeless Tobacco Product Modified Risk Claims I: Consumer Product Demand

NCT07102082
View directory record Official record
Conditions
Smoking Behaviors
Interventions
Modified Risk - None, Modified Risk Claim
Behavioral
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Nov 15, 2026, 5:15 AM EST
Completed Phase 3 Interventional

Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV

NCT00086359
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, lamivudine, and zidovudine, Lamivudine/zidovudine, Lopinavir/ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 15, 2026, 5:15 AM EST
Completed No phase listed Observational

Prospective Observation of Cardiac Safety With Proteasome Inhibition

NCT02178579
View directory record Official record
Conditions
Heart Failure, Multiple Myeloma
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Nov 15, 2026, 5:15 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib

NCT05868356
View directory record Official record
Conditions
Healthy Adults
Interventions
Treatment A, Treatment B
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Nov 15, 2026, 5:15 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine

NCT05857566
View directory record Official record
Conditions
Drug-induced Weight Gain
Interventions
RDX-002 + Olanzipine, Olanzapine
Drug
Lead sponsor
Response Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 15, 2026, 5:15 AM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals

NCT02536846
View directory record Official record
Conditions
Healthy
Interventions
Olanzapine
Drug
Lead sponsor
Dost Ongur
Other
Eligibility
21 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Nov 15, 2026, 5:15 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep

NCT00893269
View directory record Official record
Conditions
Marijuana Dependence
Interventions
eszopiclone, Placebo, ramelteon, zolpidem
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Nov 15, 2026, 5:15 AM EST